UNSPSC 51102836: Dexamethasone/tobramycin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102836 Dexamethasone/tobramycin is a Commodity code covering pharmaceutical products, though recent state and local solicitations tagged under this code show limited alignment with the nominal scope. The Illinois Department of Public Health and Seminole County, Florida have posted opportunities in this space, but neither directly solicits dexamethasone/tobramycin formulations. Instead, recent activity reflects broader pharmaceutical procurement — the Illinois Department of Public Health's completed MMCAP Infuse piggyback contract with Chartwell Rx LLC (August 2026) supplied antibiotics (Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg) through a cooperative purchasing vehicle, while Seminole County's IFB (posted June 2026) sought naloxone and drug deactivation systems for community health delivery. State and local health departments and county health authorities are the primary issuing bodies under this code's recent activity. The Illinois opportunity used an Invitation for Bid process with a $2,999,999.11 total award value over three years including renewals; Seminole County's procurement required quarterly deliveries to its Community Health Building in Sanford with a two-year initial term and one-year renewal option.

Geographic activity clusters in Illinois and Florida based on recent posted opportunities. The code shows sparse recent activity specifically matching its dexamethasone/tobramycin scope — the two most recent opportunities are tagged to the code but address unrelated pharmaceutical categories (antibiotics in Illinois, emergency-response drugs in Florida). Vendors pursuing this code should note the mismatch and monitor for future postings that align more directly with the nominal product line or consider broader pharmaceutical supply positioning if pursuing cooperative purchasing frameworks like MMCAP Infuse that state health departments leverage.